Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure (RENEU-HF)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JK 07 (Primary)
Indications Chronic heart failure
Focus Adverse reactions; Therapeutic Use
Acronyms RENEU-HF
Sponsors SalubrisBio

Most Recent Events

22 Jan 2025 According to the SalubrisBio Media Release, Primary endpoint analysis is planned to be presented in 2026.
22 Jan 2025 Positive interim results presented in the SalubrisBio Media Release.
22 Apr 2024 According to a Salubris Biotherapeutics media release, first patient has been enrolled in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com